MiNK Therapeutics Business Summary

MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company that operates as a pre-revenue entity, deriving value through the discovery and development of allogeneic invariant natural killer T (iNKT) cell therapies. The company’s business model centers on its proprietary platform for scalable, off-the-shelf manufacturing of native and engineered iNKT cells, with primary business segments targeting oncology (solid tumors and multiple myeloma), pulmonary inflammation (ARDS), and immune-mediated diseases such as Graft-versus-Host Disease (GvHD). MiNK currently funds operations through capital raises and strategic support from its parent company, Agenus Inc., with a long-term revenue strategy focused on licensing and the eventual commercialization of its lead candidate, agenT-797. Within the competitive landscape, MiNK competes with cell therapy developers such as Nkarta Therapeutics, Allogene Therapeutics, and Poseida Therapeutics, positioning itself as a specialist in iNKT cells which offer unique tissue-homing and immune-regulatory advantages over traditional CAR-T or NK cell platforms. The leadership team is anchored by President and CEO Dr. Jennifer S. Buell, who possesses over 27 years of industry experience and formerly served as President and COO of Agenus. Key executive roles include Christine M. Klaskin as Treasurer and Principal Financial Officer, and Marco Purbhoo as Head of Translational Medicine, while Dr. Marc van Dijk serves as a Scientific Advisor following his tenure as the company's CSO and CTO of Agenus. The company has recently bolstered its strategic depth with the appointment of Dr. Terese C. Hammond to lead inflammatory and pulmonary programs and the addition of notable board members including Colonel (Ret.) John B. Holcomb, a global authority in trauma care, and Dr. Robert Kadlec, a former U.S. Assistant Secretary for Preparedness and Response. MiNK’s investor profile is dominated by Agenus Inc., which holds a strategic stake of approximately 55%, supported by institutional shareholders such as Vanguard Group, Longbow Finance, and Renaissance Technologies.